pharma · Advanced Solid Tumor · RNAZ
Transcode Therapeutics
Transcenta Therapeutics is a pharma organization headquartered in Princeton, USA. It trades on NYSE under ticker RNAZ. Primary therapeutic focus areas include Advanced Solid Tumor. NovaPharmaNews links 2 clinical program
Company details
- Status
- Public
- HQ
- Princeton, USA
- Employees
- 93
- Programs
- 2
- Drugs
- 0
- Patents
- 0
TTX-MC138
Phase 2 · small molecule · Advanced Solid Tumor
TTX-MC138 for Advanced Solid Tumor is a Phase 2 program (small_molecule) at Transcode Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code TTX-MC138-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Transcode Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advanced Solid Tumor
- Status
- active
- Trials
- 1